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EDITORIAL – BREAST ONCOLOGY

Just Say No: The Case Against Opioid-Based Postoperative Pain
Management Regimens Following Breast Surgery
Theresa Schwartz
Breast Surgical Oncology, Henry Ford Health System, Detroit

Despite losing coverage in the headlines and priority
among legislators due to the COVID-19 global health
pandemic, the opioid crisis continues to wreak havoc
across the country. Nearly 71,000 drug overdose deaths
were reported by the Centers for Disease Control (CDC) in
2019, with over 50,000 of these deaths involving opioids.1
It can trace its roots to the early 1990s when financial,
ethical, and regulatory pressures, as well as false reassurances from pharmaceutical companies regarding the
addictive nature of opioids, resulted in the encouragement
of liberal use of opioids to control pain.2 The opioid epidemic blossomed due to altruistic efforts by physicians and
surgeons attempting to provide compassionate patient care.
The increased use of opioids subsequently resulted in
widespread diversion and misuse, and current data suggest
that 80% of people who use heroin first misused prescription opioids.3 This trend is both deadly and expensive.
The CDC estimates that the total economic burden of
prescription opioid misuse alone in the USA is US$78.5
billion per year, including the costs of healthcare, lost
productivity, addiction treatment, and criminal justice
involvement.4
For many patients addicted to opioids, filling a prescription after an operation was where it all began.
Approximately 6% of previously opioid-naı̈ve patients
continue to use opioids more than 3 months after an
operation.5 Without data to guide management of acute
postoperative pain, most patients are prescribed more
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narcotics than necessary. In a systematic review of 810
postoperative patients in 2017, 67–92% reported unused
opioids.6 The vast majority (around 75%) of these patients
stored the extra opioids in unlocked locations, and less than
10% were discarded according to an appropriate disposal
method, offering unlimited opportunities for diversion.
Since the opioid epidemic was declared a public health
emergency in 2017, priority has been placed on developing
evidence-based strategies to both adequately treat postoperative acute pain and mitigate the consequences and side
effects of the treatment provided.
In this issue of Annals of Surgical Oncology, Morin
et al.7 add to the growing body of literature supporting nonopioid-based regimens for postoperative pain management
following breast surgery. In their nonrandomized study,
postoperative pain scores were compared amongst two
cohorts of patients undergoing partial mastectomies—those
who received an opioid-sparing regimen as part of a
prospective pilot study (operation performed September
2017 to April 2019) and historical patients who were discharged with an opioid-based regimen (operation
performed July 2015 to June 2016). The opioid-sparing
regimen included preoperative education, gabapentin and
acetaminophen given in holding, intraoperative liposomal
bupivacaine and ketorolac, as well as postoperative acetaminophen and ibuprofen. They excluded patients with
history of opioid dependence or chronic use as well as
patients undergoing mastectomy or axillary surgery alone.
Patients in the opioid-sparing group reported statistically
significantly less pain on postoperative day 1 than patients
in the traditional opioid group: 19.1% versus 34.3%
reported moderate pain (p \ 0.001), and 6.9% versus
15.7% reported severe pain (p = 0.004). By postoperative
day 7, the opioid-sparing group still reported less pain, but
it did not reach statistical significance. The authors
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conclude that an opioid-sparing protocol following partial
mastectomy is feasible, given its superior postoperative
pain control compared with an opioid-based regimen.
Several prior studies confirm these findings. Kang et al.8
developed an opioid-sparing pathway for patients undergoing breast-conserving surgery with preoperative
acetaminophen, pre-incision bupivacaine infiltration, postexcision bupivacaine wound deposition, intraoperative
ketorolac, and postoperative acetaminophen and ibuprofen.
Of the 226 patients treated with this regimen, 99% reported
adequate pain control without opioids. Moo et al.9 similarly
found successful pain control after breast-conserving surgery without narcotics. This group used intraoperative
acetaminophen and ketorolac as well as operative site
infiltration of bupivacaine and a discharge regimen of
diclofenac and acetaminophen. Postoperative pain scores
were statistically similar to their control group receiving
opioids at discharge, suggesting no clinical necessity for
opioids. Rojas et al.10 outlined a pilot Enhanced Recovery
After Surgery (ERAS) protocol with many of the standard
elements seen in other ERAS protocols. This group included preoperative counseling, acetaminophen, and
gabapentin in holding, liposomal bupivacaine prior to
incision as well as at time of closure, intraoperative
ketorolac, and a discharge regimen of ibuprofen and acetaminophen. Comparing the pilot group with one receiving
opioids, they found no statistically significant difference in
postoperative pain scores.
We have the data to support adequate pain control
without opioids following breast surgery. So why does it
seem so difficult to change prescribing habits? The
importance of one piece of ERAS protocols that makes
them successful cannot be underestimated—preoperative
counseling on postoperative expectations. Most patients are
afraid of having pain and can be hesitant about a regimen
that only includes over-the-counter medications. They may
assume that it will not be enough and want an opioid
prescription ‘‘just in case.’’ Surgeons may fear being perceived as uncaring if they do not prescribe opioids. All
fears, assumptions, and perceptions can be alleviated by a
conversation with our patients prior to operation. Providing
educational materials on the dangers of opioid use and the
deadly effects of diversion, as well as a description of the
pain regimen being prescribed, would give confidence to
patients regarding the benefits of an opioid-sparing protocol. This is not an easy request, as all surgeons are being
asked to do more in less time, but our prescribing habits
have a tremendous impact on the opioid epidemic. We
cannot just watch from the sidelines.
A one-paragraph letter to the editor written in the New
England Journal of Medicine (NEJM) in 1980 titled
‘‘Addiction Rare in Patients Treated with Narcotics’’
reported only four opioid addictions in nearly 12,000

patients who received at least one opioid while hospitalized. Despite only including patients being treated in a
controlled in-patient setting with medications delivered as
prescribed, with no data provided, this 101-word letter has
been cited 608 times. In 2017, a correspondence was
written in the NEJM11 outlining the unintended effects of
this letter—and noted that 72% of the authors who cited it
did so as evidence that addiction was rare in patients
treated with opioids, over 80% of the authors who cited it
did not note that the patients they reference in the letter
were hospitalized at the time of opioid administration, and
other authors grossly misrepresented the conclusions. Why
was it so easy to believe five sentences of commentary, yet
so difficult to trust the numerous well-designed studies
showing how opioid-sparing regimens provide adequate
postoperative pain control? Opioids simply are not necessary. We have the data. It is time for all surgeons to start
using it.
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